Mice were immunized subcutaneously with either killed cells or a ribosome-containing fraction (RF) obtained from Vibrio cholerae Ogawa 41. At appropriate time intervals, these mice or their progeny were challenged with uniformly lethal doses of Ogawa or Inaba serotype. Half of the offspring born to mice immunized with 20 ,ug of RF were protected against homologous challenge at 7.5 weeks of age, and significant protection was observed up to 15 weeks of age. Similar protection was observed with heterologous challenge, but the duration of protection was reduced. The duration of protection obtained in newborns was related to the quantity of RF given to the mother. Protection was transferred from mother to young via colostrum or milk. Protection was not due to transfer of antigen, as active immunity could not be induced in newborn mice immunized with RF.
Although infection of the mouse with Vibrio cholerae has long been used as a method of evaluating potential cholera vaccines, the mechanism of immunity to infection in the mouse has received little study (13, 25) . Vibrio-agglutinating and vibriocidal antibody are readily demonstrated, and Watanabe et al. have suggested that the mouse protective and vibriocidal antibody might be the same (32) . As with other gram-negative bacteria, the vibriocidal antibodies are thought to be specific for the determinants of lipopolysaccharide (15, 19, 20, 32) . Vibriocidal antibodies, directed against a protein antigenically distinct from lipopolysaccharide and common to Inaba and Ogawa strains, have been reported (22) .
Passive transfer of immunity to experimental cholera infection from mother to infant rabbit has been demonstrated (24) . It was concluded from this work that this protection was the result of placental transmission of cholera antibodies. It was also shown that antisera made in rabbits to live vibrio were capable of passively protecting mice and rabbits against challenge with V. cholerae or a toxic lysate (23) . Recently, Ujiiye et al. have shown that suckling mice are susceptible to oral cholera infection (31) . Mice born to immunized mothers were resistant to infection when challenged up to 10 days of age (30) . Passive transfer of protection was associated with immune milk. We The challenge data indicated no difference in response of male or female parents nor between male or female newborns. The data obtained from both sexes were pooled and are shown in Fig. 1 and 2 . Mice born to parents immunized with either V. cholerae Ogawa whole cells or RF were found to be resistant to challenge with either Ogawa or Inaba serotypes. Half of the mice challenged with the homologous organism survived at 7.5 weeks of age, and significant protection was observed at 15 weeks of age (Fig. 1) . Similar results were obtained with the heterologous challenge except that the duration of protection was shorter (Fig. 2) . At Table 4 show that transfer of immune serum resulted in solid protection even at the longest time interval studied (16 days) . Serum obtained from the survivors of this homologous challenge had a mean vibriolytic titer of 1 :8.
DISCUSSION
The experiments reported here clearly show that mice born to mothers immunized with either V. cholerae Ogawa whole cell vaccine or RF were resistant to infection when challenged parenterally with either homologous or heterologous serotype. A similar protection has been reported for several parasitic protozoan infections in the rat (7, 9, 29, 33 ). Panse and Dutta have shown that 10-day-old rabbits born to mothers immunized with live cholera vaccine were immune to infection (23) . Suckling mice nursed for 6 to 7 days on mothers immunized with whole cells of V. cholerae were resistant to oral or parenteral challenge with the homologous (Inaba) serotype (30) . None of the studies with vibrios was designed to examine the duration of protection, which was found to be extended in our studies.
Significant protection with homologous (Ogawa) challenge in mice born to RF-immuned mothers was observed at 15 (30) . Immunity in piglets to swine influenza has also been shown to be transferred in the milk (3) .
The protection observed in suckling mice may be due to transfer of a protective antibody in the milk. The absorption of intact globulins from the gut of young rabbits, rats, and mice has been studied extensively (4, 5, 6, 8, 16, 17) . In rats, the amount of globulin absorbed was proportional to concentration and inversely proportional to the age of the recipient. No absorption was observed after 20 days of age. Mice were found to absorb antibody globulins up to 15 to 17 days of age (18, 21) . Furthermore, mice nursed on immune mothers were found to have serum vibriocidal titers. Transfer of solid protection to newborns could be achieved with immune serum. This protection was evident for at least 16 days after administration of immune serum, the longest time interval studied. Passive administration of immune V. cholerae serum has been previously reported to be protective for rabbits and mice when administered 4 to 6 hr prior to infection (12, 24 (28) .
Studies of the type reported here should give insight to the dynamics of infection in the mouse and may be applicable to the development of improved cholera vaccines. The mouse model has been employed for the testing and standardization of cholera vaccines (13) . The mechanism of protection in this system is not fully understood but is apparently linked to the production of a vibriocidal antibody in response to cell wall antigens (32 In nature, the disease is limited to the gut and produces symptoms which can be attributed to the production of an enterotoxin (choleragen) (14) . (11, 14) and mouse (31) as well as the adult dog (26, 27) and chinchilla (1) . The obvious advantages of using suckling mice as experimental animals is, in part, negated by the fact that these mice do not respond to immunization. Alternate systems have been described where suckling rabbits or mice are nursed on mothers immunized with experimental vaccines (11, 24, 31) . These systems may only be of use in demonstrating immunity due to some humoral factor.
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